SuperworthSTERIS STE
- Market cap
- $22.6B
- PE
- 28.4×
- 7y median 40.5×
- Forward PE
- 20.2×
- 10y median 24.3×
- Price to sales
- 3.7×
- EV/EBIT
- 21.0×
- Revenue, 12 months
- $6B
- +8% on a year ago
- Net margin
- 13.3%
- Free cash flow yield
- 4.1%
STERIS trades at 28.4× trailing earnings, cheaper than 95% of the last ten years. Revenue was $6B over the last twelve months, up 8% on a year earlier with a 13% net margin.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2B+14% | $1.3B+17% | $1.4B+11% | $1.3B+8% | $1.3B+7% | $1.4B+6% | $1.5B+4% | $1.4B+9% | $1.5B+10% | $1.5B+9% | $1.6B+7% | $1.5B+7% | |
| Cost of revenue | $692M+14% | $737.7M+16% | $836.5M+14% | $707.1M+8% | $750.1M+8% | $760.2M+3% | $839.3M+0% | $763.1M+8% | $814.4M+9% | $840.7M+11% | $891.2M+6% | $808.6M+6% |
| Gross profit | $546.2M+13% | $560M+17% | $582.9M+7% | $572.4M+8% | $578.8M+6% | $610.3M+9% | $641.2M+10% | $628M+10% | $645.9M+12% | $655.5M+7% | $697.1M+9% | $684.2M+9% |
| R&D | $26.3M+5% | $25.3M−1% | $27.5M+4% | $25.6M+4% | $27M+3% | $27.4M+8% | $27.7M+1% | $26.4M+3% | $28.2M+4% | $29.5M+8% | $28.8M+4% | $28.6M+8% |
| SG&A | $328.4M+2% | $308.3M+1% | $309.1M−8% | $335.6M+10% | $329.3M+0% | $335.4M+9% | $333.9M+8% | $353.8M+5% | $349.7M+6% | $352.3M+5% | $351.8M+5% | $369.7M+5% |
| $191.6M | $226.5M+19% | $220.3M−2% | $185.5M−6% | $219.7M+15% | $245.3M+8% | $216.2M−2% | $246M+33% | $265.8M+21% | $273.2M+11% | $316.8M+47% | $285.8M+16% | |
| Interest expense | $36.9M+41% | $38.9M+36% | $36.1M+18% | $30.4M−6% | $19.7M−47% | $19.1M−51% | $17.1M−53% | $15.9M−48% | $14.9M−24% | $14.9M−22% | $15.1M−12% | $15.8M−1% |
| Pre-tax income | $155.9M−2% | $189.6M+11% | $190.6M−6% | $175.2M+5% | $194.9M+25% | $228.7M+21% | $197.3M+4% | $231.9M+32% | $253.1M+30% | $257.8M+13% | $304.5M+54% | $273.5M+18% |
| $35.1M−1% | $41M+1% | $37.3M+76% | $35.3M−3% | $43.5M+24% | $55.4M+35% | $50.5M+35% | $53.9M+53% | $60.6M+39% | $63.5M+15% | $84.2M+67% | $72.5M+35% | |
| Net income | $115.3M | $140.7M+14% | −$1.4M | $145.4M+18% | $150M+30% | $173.5M+23% | $145.7M | $177.4M+22% | $191.9M+28% | $192.9M+11% | $220.2M+51% | $200.1M+13% |
| $1.16 | $1.42+15% | −$0.01 | $1.46+17% | $1.51+30% | $1.75+23% | $1.48 | $1.79+23% | $1.94+29% | $1.96+12% | $2.24+51% | $2.04+14% | |
| 99.4M−1% | 99.4M−1% | 98.9M−1% | 99.4M+0% | 99.2M−0% | 98.9M−1% | 98.7M−0% | 98.8M−1% | 98.8M−0% | 98.6M−0% | 98.4M−0% | 97.9M−1% |
EPS, diluted: 6 periods, Q1 FY20 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q2 FY27 | $1.6B | $1.5B to $1.6B | $2.68 | $2.67 to $2.69 | 3 |
| Q3 FY27 | $1.6B | $1.6B to $1.6B | $2.81 | $2.80 to $2.84 | 3 |
| Q4 FY27 | $1.7B | $1.7B to $1.7B | $3.15 | $3.12 to $3.18 | 1 |
| Q1 FY28 | $1.6B | $1.6B to $1.6B | $2.83 | $2.80 to $2.86 | 1 |
| Q2 FY28 | $1.7B | $1.6B to $1.7B | $2.95 | $2.91 to $2.98 | 1 |
| Q3 FY28 | $1.7B | $1.7B to $1.7B | $3.07 | $3.04 to $3.11 | 1 |
| Q4 FY28 | $1.8B | $1.8B to $1.8B | $3.44 | $3.40 to $3.48 | 2 |
| Q1 FY29 | $1.7B | $1.7B to $1.7B | $3.07 | $3.03 to $3.10 | 2 |
Peers
Companies in Healthcare nearest STERIS' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| STESTERIS | $22.6B | 28.4× | 40.5× | 20.2× | 3.7× | +8% | 13.3% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| THCTenet Healthcare | $21.6B | 10.4× | 11.2× | 12.9× | 1.0× | +5% | 10.3% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| WSTWest Pharmaceutical Services | $27.6B | 50.2× | 45.8× | 42.2× | 8.3× | +12% | 17.0% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| Peer median | $24.3B | 26.5× | 32.9× | 24.9× | 5.0× | +9% | 13.6% |
More on STERIS
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Specialties
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .